James Smith - Pfizer Independent Director
PFE Stock | USD 27.78 0.19 0.69% |
Director
Mr. James Clifton Smith is an Independent Director of Pfizer Inc. Mr. Smith is President and Chief Executive Officer and Director of Thomson Reuters Corporationrationration, a provider of intelligent information for businesses and professionals, since January 2012 and its Chief Operating Officer from September 2011 to December 2011 and Chief Executive Officer, Thomson Reuters Professional Division, from 2008 to 2011. Prior to the acquisition of Reuters Group PLC by The Thomson Corporation in 2008, served as Chief Operating Officer of Thomson and as President and Chief Executive Officer of Thomson Learnings Academic and Reference Group. Member of the International Business Council of the World Economic Forum, the International Advisory Boards of British American Business and the Atlantic Council. Mr. Smiths experience as President and CEO of Thomson Reuters brings valuable leadership, finance, international business, talent and management skills to our Board. Pfizer benefits from Mr. Smiths organizational expertise and leadership experience, honed in numerous senior management roles and on notable merger and acquisition activity, including the acquisition and subsequent integration of two of the information industrys preeminent firms, as well as his strong operational and international expertise since 2014.
Age | 61 |
Tenure | 10 years |
Address | 66 Hudson Boulevard East, New York, NY, United States, 10001-2192 |
Phone | 212 733 2323 |
Web | https://www.pfizer.com |
Pfizer Management Efficiency
The company has Return on Asset of 0.0155 % which means that on every $100 spent on assets, it made $0.0155 of profit. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of 0.0235 %, implying that it generated $0.0235 on every 100 dollars invested. Pfizer's management efficiency ratios could be used to measure how well Pfizer manages its routine affairs as well as how well it operates its assets and liabilities. As of March 28, 2024, Return On Capital Employed is expected to decline to 0.02. In addition to that, Return On Assets is expected to decline to 0.01. At present, Pfizer's Non Current Assets Total are projected to increase significantly based on the last few years of reporting. The current year's Other Current Assets is expected to grow to about 9.7 B, whereas Total Current Assets are forecasted to decline to about 32.2 B.Similar Executives
Showing other executives | DIRECTOR Age | ||
Anthony Tjan | Equillium | N/A | |
Heidi Kunz | Agilent Technologies | 66 | |
Helena Herlogsson | 23Andme Holding Co | N/A | |
James Daly | Madrigal Pharmaceuticals | N/A | |
Richard Kender | Seres Therapeutics | 62 | |
Anders Forseback | 23Andme Holding Co | N/A | |
Giuseppe Lettieri | 23Andme Holding Co | 33 | |
Richard Levy | Madrigal Pharmaceuticals | 60 | |
Arturo Testa | 23Andme Holding Co | 37 | |
Peter Hutt | Seres Therapeutics | 80 | |
Donald Kufe | Madrigal Pharmaceuticals | 69 | |
David Berry | Seres Therapeutics | 37 | |
Charles McDermott | Equillium | 45 | |
Mark Pruzanski | Equillium | 50 | |
Willard Dere | Seres Therapeutics | 64 | |
Salvatore Falco | 23Andme Holding Co | 46 | |
Vincenzo Capizzi | 23Andme Holding Co | N/A | |
Robert Wilson | Madrigal Pharmaceuticals | 75 | |
Frederick Craves | Madrigal Pharmaceuticals | 72 | |
Bo Eriksson | 23Andme Holding Co | 65 | |
Ettore Artioli | 23Andme Holding Co | N/A |
Management Performance
Return On Equity | 0.0235 | ||||
Return On Asset | 0.0155 |
Pfizer Inc Leadership Team
Elected by the shareholders, the Pfizer's board of directors comprises two types of representatives: Pfizer inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Pfizer. The board's role is to monitor Pfizer's management team and ensure that shareholders' interests are well served. Pfizer's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Pfizer's outside directors are responsible for providing unbiased perspectives on the board's policies.
Jennifer Damico, Senior Vice President Principal Accounting Officer, Controller | ||
Douglas Lankler, Executive Vice President General Counsel | ||
Shantanu Narayen, Lead Independent Director | ||
Mikael Dolsten, Chief Scientific Officer, President - Worldwide Research, Development and Medical | ||
Susan DesmondHellmann, Independent Director | ||
Stephen Sanger, Independent Director | ||
Lidia Fonseca, Executive Vice President, Chief Technology Officer and Digital Officer | ||
Aamir Malik, Executive Vice President Chief Business Innovation Officer | ||
Christopher Stevo, Senior Vice President and Chief Investor Relations Officer | ||
Geno Germano, Group President of Global Innovative Pharma Bus. | ||
Laurie Olson, Executive Vice President - Strategy, Portfolio and Commercial Operations | ||
William Carapezzi, Executive Vice President - Global Business Services and Transformation | ||
Rady Johnson, Chief Compliance, Quality and Risk Officer, Executive Vice President | ||
Mikael MD, Chief Development | ||
Payal Becher, Chief VP | ||
James Quincey, Independent Director | ||
Charles Hill, Executive Vice President - Worldwide Human Resources | ||
Albert Bourla, Group President - Vaccines, Oncology and Consumer Healthcare Business | ||
Payal Sahni, Executive Vice President, Chief People Experience Officer | ||
Kirsten LundJurgensen, Executive Vice President and Presidentident - Pfizer Global Supply | ||
Angela Hwang, Group President - Pfizer Biopharmaceuticals Group | ||
Mike Mcdermott, Executive Vice President Chief Global Supply Officer | ||
Kathrin Jansen, Senior Vice President - Vaccine Research & Development | ||
John Young, Group President - Pfizer Innovative Health and Angela Hwang | ||
Frank DAmelio, Chief Financial Officer, Executive Vice President - Business Operations and Global Supply | ||
Dawn Rogers, Chief Human Resource Officer, Executive Vice President | ||
Helen Hobbs, Independent Director | ||
James Smith, Independent Director | ||
Christopher CFA, VP Officer | ||
Dennis Ausiello, Independent Director | ||
Michael Mcdermott, Executive Vice President Chief Global Supply Officer | ||
Francesca DeMartino, Chief Officer | ||
Frances Fergusson, Independent Director | ||
Gordon Loh, Senior Vice President Corporate Audit | ||
Wyllie Cornwell, Independent Director | ||
Suzanne Johnson, Independent Director | ||
David Denton, Chief VP | ||
Alexander Mackenzie, Executive Vice President Chief Development Officer | ||
DVM DVM, Chairman CEO | ||
William Gray, Independent Director | ||
Sally Susman, Chief Corporate Affairs Officer, Executive Vice President | ||
Anthony Maddaluna, Executive Vice President and Presidentident - Pfizer Global Supply | ||
Susan Hockfield, Independent Director | ||
Freda LewisHall, Executive Vice President Chief Medical Officer | ||
Albert DVM, Chairman CEO | ||
Dan Littman, Independent Director | ||
Ian Read, Chairman, CEO and Chairman of Executive Committee | ||
James Kilts, Independent Director | ||
Don Cornwell, Independent Director | ||
Andreas Panayiotou, Global Officer | ||
Joseph Echevarria, Independent Director | ||
Scott Gottlieb, Independent Director | ||
Ronald Blaylock, Independent Director | ||
Michael Goettler, Group President - Pfizer Upjohn |
Pfizer Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Pfizer a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Return On Equity | 0.0235 | ||||
Return On Asset | 0.0155 | ||||
Profit Margin | 0.04 % | ||||
Operating Margin | (0.50) % | ||||
Current Valuation | 214.38 B | ||||
Shares Outstanding | 5.66 B | ||||
Shares Owned By Insiders | 0.04 % | ||||
Shares Owned By Institutions | 69.96 % | ||||
Number Of Shares Shorted | 66.12 M | ||||
Price To Earning | 9.48 X |
Pfizer Investors Sentiment
The influence of Pfizer's investor sentiment on the probability of its price appreciation or decline could be a good factor in your decision-making process regarding taking a position in Pfizer. The overall investor sentiment generally increases the direction of a stock movement in a one-year investment horizon. However, the impact of investor sentiment on the entire stock market does not have solid backing from leading economists and market statisticians.
Investor biases related to Pfizer's public news can be used to forecast risks associated with an investment in Pfizer. The trend in average sentiment can be used to explain how an investor holding Pfizer can time the market purely based on public headlines and social activities around Pfizer Inc. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
Pfizer's market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Pfizer's and other traded tickers. The bigger the bubble, the more accurate is the estimated score. Higher bars for a given day show more participation in the average Pfizer's news discussions. The higher the estimated score, the more favorable is the investor's outlook on Pfizer.
Pfizer Implied Volatility | 52.55 |
Pfizer's implied volatility exposes the market's sentiment of Pfizer Inc stock's possible movements over time. However, it does not forecast the overall direction of its price. In a nutshell, if Pfizer's implied volatility is high, the market thinks the stock has potential for high price swings in either direction. On the other hand, the low implied volatility suggests that Pfizer stock will not fluctuate a lot when Pfizer's options are near their expiration.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Pfizer in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Pfizer's short interest history, or implied volatility extrapolated from Pfizer options trading.
Becoming a Better Investor with Macroaxis
Macroaxis puts the power of mathematics on your side. We analyze your portfolios and positions such as Pfizer Inc using complex mathematical models and algorithms, but make them easy to understand. There is no real person involved in your portfolio analysis. We perform a number of calculations to compute absolute and relative portfolio volatility, correlation between your assets, value at risk, expected return as well as over 100 different fundamental and technical indicators.Build Optimal Portfolios
Align your risk with return expectations
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Pfizer Inc. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in census. Note that the Pfizer Inc information on this page should be used as a complementary analysis to other Pfizer's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Fundamentals Comparison module to compare fundamentals across multiple equities to find investing opportunities.
Complementary Tools for Pfizer Stock analysis
When running Pfizer's price analysis, check to measure Pfizer's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Pfizer is operating at the current time. Most of Pfizer's value examination focuses on studying past and present price action to predict the probability of Pfizer's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Pfizer's price. Additionally, you may evaluate how the addition of Pfizer to your portfolios can decrease your overall portfolio volatility.
Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
Bonds Directory Find actively traded corporate debentures issued by US companies | |
ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals |
Is Pfizer's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Pfizer. If investors know Pfizer will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Pfizer listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.76) | Dividend Share 1.64 | Earnings Share 0.37 | Revenue Per Share 10.366 | Quarterly Revenue Growth (0.41) |
The market value of Pfizer Inc is measured differently than its book value, which is the value of Pfizer that is recorded on the company's balance sheet. Investors also form their own opinion of Pfizer's value that differs from its market value or its book value, called intrinsic value, which is Pfizer's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Pfizer's market value can be influenced by many factors that don't directly affect Pfizer's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Pfizer's value and its price as these two are different measures arrived at by different means. Investors typically determine if Pfizer is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Pfizer's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.